New targeted drug shows promise for Hard-to-Treat cancers
NCT ID NCT05161390
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 29 times
Summary
This study tested an experimental drug called LM-302 in 153 adults with advanced solid tumors that have a specific protein (CLDN18.2). The goal was to find a safe dose and see if the drug can shrink tumors. Participants received the drug intravenously, and researchers monitored side effects and how the drug moved through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.